]> 2026-04-12T04:08:01-07:00 ABT-414 0 en The drug ABT-414 is in phase 1 of its clinical trials. It demonstrates a tendency towards eye toxicities, especially causing blurred vision. This is an indication of potentially high toxicity. However, due to small sample size and other variables in the study, the evaluations should be taken with caution. It is advised to expect a higher level of toxicity until tested further in next clinical trial phases. 2025-01-18T08:21:21Z 2460693.8481597 ABT-414 Has treatment name 102 en Has treatment name